GLP-3 RT (10mg)
Technische Spezifikationen
| Reinheit (HPLC) | ≥97% (HPLC) |
| CAS-Nummer | 2381089-83-2 |
| Form | White lyophilized powder |
| Lagerung | -20°C |
| Sequenz | Modified triple incretin agonist |
| Molekulargewicht | 4,803.56 g/mol |
| Salzform | Acetate |
| Löslichkeit | Soluble in aqueous buffer |
GLP-3 RT (10mg)
EUR-Listenpreis · HU, SK, CZ, PL
- Eurozone (EUR)252,00 EUR
- Ungarn (HU)252,00 EUR≈ 100 800 Ft
- Slowakei (SK)252,00 EUR
- Tschechien (CZ)252,00 EUR≈ 6 300 Kč
- Polen (PL)252,00 EUR≈ 1071,00 zł
Gleicher EUR-Listenpreis für Lieferung nach Ungarn, Slowakei, Tschechien und Polen. Abrechnung in EUR.
HUF/CZK/PLN sind indikativ aus EUR umgerechnet; die Slowakei nutzt EUR. Kurse annähernd. Abrechnung in EUR.
Retatrutid — dreifacher Inkretin-Agonist (GLP-1R, GIPR, GCGR); im Fokus von Forschungspublikationen zu Stoffwechsel und Körpergewicht. Lagerung bei −20 °C. Nur RUO — ausschließlich für Laborforschung; nicht zum menschlichen Verzehr.
Ausschließlich für Laborforschung.
Nicht für den menschlichen Verzehr, tierärztliche oder diagnostische Zwecke.
From the Peptide Explorer
The first triple-incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data demonstrated the largest weight reductions reported for any anti-obesity molecule, positioning it as a next-generation metabolic research compound.
Key Mechanisms
- ›GIP receptor agonism
- ›GLP-1 receptor agonism
- ›Glucagon receptor agonism (energy expenditure)
- ›Hepatic lipid metabolism enhancement
- ›Appetite suppression via CNS pathways
Primary Research Areas
- ›Obesity
- ›NASH
- ›Metabolic syndrome
- ›Triple-incretin signaling
- ›Energy expenditure
Key Research Findings
- Phase 2: up to 24.2% body weight reduction at 48 weeks (highest reported for any molecule)
- Glucagon component uniquely increases energy expenditure
- Significant reduction in liver fat content in NAFLD models
Research Overview
The first triple-incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data demonstrated the largest weight reductions reported for any anti-obesity molecule, positioning it as a next-generation metabolic research compound.
Origin: Triple GIP/GLP-1/glucagon receptor agonist by Eli Lilly
Mechanism of Action
- GIP receptor agonism
- GLP-1 receptor agonism
- Glucagon receptor agonism (energy expenditure)
- Hepatic lipid metabolism enhancement
- Appetite suppression via CNS pathways
Primary Research Areas
- Obesity
- NASH
- Metabolic syndrome
- Triple-incretin signaling
- Energy expenditure
Key Published Findings
- Phase 2: up to 24.2% body weight reduction at 48 weeks (highest reported for any molecule)
- Glucagon component uniquely increases energy expenditure
- Significant reduction in liver fat content in NAFLD models
Research Protocol
Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
2-8°C
Important Notice
Retatrutide (10mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Forschungsspezifikationen
Synthesized for strict analytical consistency. Verified via HPLC/MS.Qualitätsstandards ansehen →
Handhabung & Lagerung
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in aqueous buffer
Häufige Fragen
What is GLP-3 RT (10mg)?▼
Is GLP-3 RT (10mg) intended for human consumption?▼
How do you verify purity and identity?▼
How should GLP-3 RT (10mg) be stored?▼
Do you provide a Certificate of Analysis (COA)?▼
What purity is GLP-3 RT (10mg)?▼
Verified Research Reviews
Reta is amazing
"really amazing compound and interesting "